Synergy Pharmaceuticals Announces Data Presentations on Plecanatide and SP-333 at Two Scientific Meetings

  Synergy Pharmaceuticals Announces Data Presentations on Plecanatide and
  SP-333 at Two Scientific Meetings

Business Wire

NEW YORK -- October 3, 2013

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on
plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in
development for gastrointestinal (GI) disorders, will take place at two
scientific meetings this month.

Plecanatide, Synergy’s lead GC-C agonist for chronic idiopathic constipation
and irritable bowel syndrome with constipation, will be featured in two oral
presentations at the United European Gastroenterology (UEG) Week being held
October 12-16 in Berlin, Germany.

Updated pre-clinical data on SP-333, the company’s next-generation GC-C
agonist being studied for opioid-induced constipation and inflammatory bowel
disease, will be featured in two poster presentations at the American College
of Gastroenterology (ACG) Annual Scientific Meeting being held October 11-16
in San Diego, California.

Plecanatide Oral Presentations - UEG 2013

Abstract: Acceleration of Time to First Bowel Movement in Chronic Idiopathic
Constipation (CIC) Patients Receiving Plecanatide in a Large, Multicenter,
Dose-Ranging Study
Date & Time: Tuesday, October 15^th, 8:42am – 8:54am
Abstract Number: OP155
Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of
Michigan)

Abstract: Plecanatide Produces a Diarrhea Plateau Effect in Chronic Idiopathic
Constipation (CIC) Patients
Date & Time: Tuesday, October 15^th, 10:18am – 10:30am
Abstract Number: OP163
Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of
Michigan)

SP-333 Poster Presentations – ACG 2013

Abstract: Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C,
Dramatically Ameliorates Morphine-Induced Bowel Dysfunction in Rats
Date & Time: Tuesday, October 15^th, 10:30am – 4:00pm
Poster Number: P1091
Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.
Note:  Recipient of, “ACG’s 2013 Presidential Poster Award.” Posters receiving
this award accumulated scores in the top five percent of the posters submitted
for the ACG Annual Meeting inSan Diego, CA.

Abstract: SP-333, a Guanylate Cyclase-C Agonist, Inhibits NF-kB Signaling and
Modulates Related Genes and miRNAs Implicated in GI Inflammation and
Carcinogenesis
Date & Time: Monday, October 14^th, 10:30am – 4:00pm
Poster Number: P1049
Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.

About Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals is a biopharmaceutical company focused on the
development of new drugs to treat patients with gastrointestinal (GI) diseases
and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a
synthetic analog of the human GI hormone, uroguanylin, and functions by
activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the
GI tract. In early 2013, Synergy announced positive results from a large
multicenter trial of plecanatide in patients with chronic idiopathic
constipation (CIC) and recently completed an end-of-phase 2 meeting with the
U.S. Food and Drug Administration (FDA) covering the registration program for
plecanatide to treat CIC. The company plans to initiate the phase 3
registration trial for plecanatide in CIC this quarter. Synergy is also
developing plecanatide for the treatment of irritable bowel syndrome with
constipation (IBS-C), recently announcing that it had reached the halfway mark
for total enrollment in a plecanatide phase 2b clinical trial in patients with
IBS-C. Synergy’s second GC-C agonist, SP-333, is in clinical development to
treat opioid-induced constipation and inflammatory bowel disease. SP-333 has
completed a phase I study in healthy volunteers and will enter phase 2 trials
for OIC in the fourth quarter of 2013. More information is available at
www.synergypharma.com .

Contact:

Synergy Pharmaceuticals
Media
Gem Gokmen
Office: 212-584-7610
Mobile: 646-637-3208
ggokmen@synergypharma.com
or
Investor
Bernard Denoyer
Office: 212-297-0020
Mobile: 203-300-8147
bdenoyer@synergypharma.com